Payment overview · 2025
General Payments
$987.47
52 reported records · 17 companies
Healthcare provider profile · identity verified
Randall E Campbell, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · TIFTON, GA · NPI 1487868576
Verified facts
What the public records show
CMS Open Payments records show Randall E Campbell, PAC received $987.47 in general payments during 2025 across 52 reported records.
Corcept Therapeutics accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $198.76 | 20.1% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $135.86 | 13.8% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $120.34 | 12.2% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.60 | 9.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.87 | 7.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.77 | 6.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.23 | 6.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $48.60 | 4.9% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.62 | 4.8% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.49 | 3.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.15 | 2.1% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $18.05 | 1.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.89 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.83 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.02 | 1.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.97 | 1.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.42 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $987.47 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $198.76 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $95.60 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $83.10 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $72.39 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.30 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $60.77 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.77 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.23 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $48.60 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $47.62 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.48 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.29 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $29.49 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.65 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 63 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 211 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
211 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 690 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 502 | 118 |
| Gabapentin | Gabapentin | 488 | 82 |
| Lisinopril | Lisinopril | 338 | 84 |
| Potassium Chloride | Potassium Chloride | 312 | 75 |
| Metformin Hcl | Metformin Hcl | 278 | 65 |
| Simvastatin | Simvastatin | 269 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 45 |
| Furosemide | Furosemide | 242 | 72 |
| Losartan Potassium | Losartan Potassium | 231 | 52 |
| Omeprazole | Omeprazole | 224 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 218 | 60 |
| Ozempic | Semaglutide | 211 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 50 |
| Meloxicam | Meloxicam | 197 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 195 | 42 |
| Allopurinol | Allopurinol | 163 | 48 |
| Famotidine | Famotidine | 149 | 33 |
| Trazodone Hcl | Trazodone Hcl | 146 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 30 |
| Montelukast Sodium | Montelukast Sodium | 142 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 31 |
| Sertraline Hcl | Sertraline Hcl | 124 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 122 | 26 |
| Tramadol Hcl | Tramadol Hcl | 117 | 25 |
| Carvedilol | Carvedilol | 103 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 25 |
| Eliquis | Apixaban | 98 | 18 |
| Donepezil Hcl | Donepezil Hcl | 94 | 22 |
| Alendronate Sodium | Alendronate Sodium | 93 | 16 |
| Buspirone Hcl | Buspirone Hcl | 90 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 27 |
| Meclizine Hcl | Meclizine Hcl | 88 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 17 |
| Azithromycin | Azithromycin | 79 | 70 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 16 |
| Prednisone | Prednisone | 76 | 52 |
| Pregabalin | Pregabalin | 76 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 13 |
| Celecoxib | Celecoxib | 71 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 12 |
| Atenolol | Atenolol | 66 | 19 |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Linzess | Linaclotide | 63 | 19 |
| Clonidine Hcl | Clonidine Hcl | 61 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 60 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 12 |
| Alprazolam | Alprazolam | 54 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 54 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | suppressed |
| Kerendia | Finerenone | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 48 | 17 |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Glipizide | Glipizide | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Febuxostat | Febuxostat | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 11 |
| Cephalexin | Cephalexin | 36 | 27 |
| Metolazone | Metolazone | 36 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 16 |
| Colchicine | Colchicine | 29 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 26 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | 13 |
| Nitroglycerin | Nitroglycerin | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 25 |
| Estradiol | Estradiol | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Humalog | Insulin Lispro | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $987.47 · 52 records | Corcept Therapeutics | AIRSUPRA, Auvelity, BREZTRI, Dexcom G6 Transmitter, FARXIGA, Kerendia, Korlym, LEQVIO, LINZESS, Leqembi, MOUNJARO, NEXLETOL, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XHANCE, XIFAXAN, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error